Increasing Diversity in Clinical Trials

There are many patient communities across various races and ethnicities that are often underrepresented in clinical trials, which creates significant gaps in the safety and efficacy data of new therapies. We’d like to advance the discussion and understand how stakeholders in clinical trials can effectively promote diversity and align with the latest FDA guidance to proactively increase the participation of underrepresented patient populations.